• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

ZymoGenetics Names Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer; Cancer Therapeutics Veteran to Oversee Clinical Development

Posted on: Wednesday, 27 July 2005, 06:00 CDT

ZymoGenetics, Inc. (NASDAQ:ZGEN) today named Dr. Nicole Onetto, previously Chief Medical Officer of OSI Pharmaceuticals, as Chief Medical Officer and Senior Vice President. Dr. Onetto will join ZymoGenetics in late September.

"We're delighted that Dr. Onetto has chosen to join ZymoGenetics," said Dr. Bruce L.A. Carter, Chairman and Chief Executive Officer of ZymoGenetics. "Her strategic vision and extensive drug development expertise will be a tremendous asset to the company."

"I am very enthusiastic with this new opportunity in my career," said Dr. Onetto. "ZymoGenetics' pipeline and broad patent estate have a large potential for new therapies in cancer, autoimmune diseases and surgical bleeding. I am looking forward to continue guiding the development of successful and innovative drugs as a member of the executive team at ZymoGenetics."

Dr. Onetto has over fifteen years of clinical drug development experience at leading biotechnology and pharmaceutical companies. Prior to joining ZymoGenetics, Dr. Onetto was Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals, where she headed the Development Organization and led the registrational program for Tarceva (TM). Prior to that, Dr. Onetto served as Senior Vice President of Medical Affairs at Gilead Sciences and was also Senior Executive at Bristol-Myers Squibb in the oncology organization. While at BMS, she was the International Project Leader for Taxol and played a key role in the filing of the initial Taxol NDA as well several supplemental NDAs. She also held clinical research positions of increasing responsibility at NeXstar Pharmaceuticals, Immunex and Hoechst. Dr. Onetto holds a Bachelor of Arts from the Academy of Paris (France), a Masters of Science in Pharmacology from the University of Montreal (Canada), a Doctor of Medicine degree from the University of Paris (France) and is also qualified in pediatrics and hematology/oncology.

About ZymoGenetics

ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in ZymoGenetics' public filings with the Securities and Exchange Commission, including ZymoGenetics' Annual Report on Form 10-K for the year ended December 31, 2004. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

Source: Business Wire

More News in this Category